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Introduction
Calpains belong to a family of cytoplasmic cysteine
proteases activated by calcium ions [1-4]. They can be
divided into two groups depending on their tissue dis-
tribution: the first group is ubiquitously present in all
tissues, and the second one is tissue-specific [5].
Among the ubiquitous calpains are the μ-calpain (cal-
pain 1), characteristic for blood cells, and m-calpain
(calpain 2), present for example in the striated muscle
[6]. These two isoforms are activated by different con-
centrations of calcium ions - m-calpain requires mil-
imolar Ca2+ concentrations  for reaching a full activity
(0.1 - 1 mM Ca2+), but μ-calpain only  micromolar 
(1 - 100 μM) Ca2+ [4,7]. 
Calpains have a very broad spectrum of action; so
far at least a hundred cellular substrates were
described. Among them there are transcription factors
(for example c-Jun, c-Fos), transmembrane receptors,
enzymes (kinases, phosphatases, caspases), cell cycle
proteins  (including p53 and cyclin D), cytoskeleton
proteins and many others [7,8]. This list of calpains'
substrates suggests their involvement in basics cellular
functions, including proliferation, apoptosis and the
general regulation of genes' expression [2,3,7,8]. In
these aspects the calpains are unique, because they not
only can cause total degradation of substrates, but -
what is more important - they are able to perform lim-
ited proteolysis, changing the substrates' activity [7].
Being so actively involved in vital cellular process-
es, the calpains need a very tight control of their pro-
teolytic activity. It is maintained by two major mecha-
nisms: first,  in every cell there is a specific, endoge-
nous inhibitor of calpain - calpastatin; and second, cal-
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pain itself is limiting its activity by autolysis [3,9].
Calpastatin is one of the calpain substrates [10,11];
its limited proteolysis by  active calpain is consid-
ered necessary for its inhibitory activity and thus it is
being postulated as an element of balance of the cal-
pain-calpastatin system, preventing uncontrolled
activity of the enzyme, and allowing its physiologi-
cal function [12]. Seventy kilodalton form of calpas-
tatin is the most often detected, native form of this
enzyme in human tissues, including the blood cells
[13].
We have shown earlier the µ-calpain overexpres-
sion in the B-cell chronic lymphocytic leukemia (B-
CLL) cells at both mRNA and protein levels and
demonstrated its high total activity correlated with low
susceptibility to apoptosis [14]. Also, we had demon-
strated there that the µ-calpain activity is greatly
decreased in the normal T and B lymphocytes obtained
from healthy elderly individuals [14]. In that study we
used the casein zymography technique, which is
detecting the total available calpain activity in the cell
lysate (proportional to enzyme concentrations in cells)
[15], but tells nothing about the actual activity of the
enzyme in the living cells. In fact, every currently
available method of assessment of calpain activity
(regardless of it being detected by zymography or by
cleavage of fluorogenic substrates) allows for estima-
tion of the total available activity of the enzyme. In our
opinion, actual calpain activity in the living cells prior
to their isolation and lysis should be of even more
physiological (and possibly pathological) relevancy,
including that related to the functions of immune cells.
Thus, in the current paper, we explore the possibility of
endogenous (actual) calpain activity measurement in
human peripheral blood T lymphocytes, through the
estimation of the proportion of native form of calpas-
tatin and its immunoreactive calpain-dependent cleav-
age  products detected by western blot and its relation
to calpain protein content in the T cells freshly isolat-
ed from peripheral blood measured by flow cytometry.
We show that the method is viable by presenting the
differences in the abovementioned proportions in the
CD4+ T cells isolated from healthy volunteers and
patients with rheumatoid arthritis (RA), and in the B-
CLL cells.
Materials and methods 
Blood donors and sample preparation. Venous blood from five
healthy volunteers, nineteen RA patients, and five B-CLL patients
was collected into the tubes with EDTA. 
Peripheral blood mononuclear cells (PBMC) were isolated by
Histopaque™ (Sigma, USA) flotation. Isolated PBMC were
washed and suspended in PBS for further studies. For the Western
blot determination of calpastatin contents, CD4+ T cells were iso-
lated from peripheral blood of healthy volunteers and RA patients,
and CD19+ B cells were isolated from peripheral blood of B-CLL
patients.
Intracellular calpain staining. Isolated PBMC (5x105 cells per
sample) were incubated with monoclonal anti-CD4 or anti-CD19
antibody conjugated with RPE-Cy5 (DAKO Cytomation) for
CD4+ or CD19+ cells identification respectively. Surface-stained
cells were fixed with 2% paraformaldehyde for 15 minutes at room
temperature. Saponin buffer  (0.25% saponin in PBS, Sigma) was
used to wash and permeabilize fixed cells. Fixed-permeabilized
cells were further resuspended in saponin buffer before adding 
20 μl of PE-anti-µ-calpain monoclonal antibody (BD Bioscience-
Pharmingen, USA, clone B27D8). After 30 minutes' incubation at
+4°C, cells were washed once with saponin buffer and then with
PBS and analyzed by flow cytometry. Appropriate fluorochrome-
conjugated irrelevant mouse immunoglobulins of corresponding
isotypes (DAKO Cytomation and BD Bioscience-Pharmingen,
USA)  were used as controls. Fluorocytometry analysis was per-
formed with the FACScan system (Becton Dickinson, USA). All
fluorocytometric data were analyzed with the WinMDI 2.9 (J. Trot-
ter, The Scripps Institute, La Jolla, CA) software.
Purification of CD4+ and CD19+ cells. CD4+ T lymphocytes were
purified from PBMC by immunomagnetic negative selection method,
using the CD4+ Negative Selection kit (Invitrogen, Dynal Biotech,
USA) according to manufacturer instructions. After separation, the
purity of CD4+ T cells was checked by flow cytometry. At least 90%
pure CD4+ T cells were used for further molecular studies. 
Purification of the CD19+ B-CLL cells was not necessary,
because all of the samples from B-CLL patients included into study
had exhibited the  proportion of CD19+CD5+ leukemia cells above
90%, as confirmed by flow cytometry. 
Detection of native and degraded calpastatin by Western blot.
Lysates from CD4+ T cells and CD19+ B-CLL cells  were prepared
using the isolation kit (Complete Lysis-M, EDTA-free, Roche) and
the protease inhibitor cocktail (leucopeptin, aprotinin, iodoac-
etamid, PMSF - all in concentration of 10 µg/ml); the amounts of
total proteins were measured by Bradford method. Purified domain
I of human calpastatin (Sigma, USA) was used in lieu of a standard
degraded fragments of the protein. Lanes were loaded with the
lysates from 1×106 cells each, corresponding to the 20 µg protein
per lane.  Protein resolution was performed by  electrophoretic sep-
aration in polyacrylamide gel under reducing conditions (SDS-
PAGE) according to Laemmli [16] in  a Mini Protean II (Bio Rad)
apparatus at room temperature, using constant  voltage  of 190 V
for  90 minutes. Electrotransfer of separated proteins from the gel
to nitrocellulose membrane (Schleicher & Schuell BioScience,
Germany), was performed by semi-dry transfer (TRANS-BLOT
SD, BioRad, USA).
The  membranes containing separated proteins were blocked
with 3% fat-free milk in TRIS-buffered saline (TBS) in order to
avoid the non-specific antibody binding. Then, the membranes
were incubated overnight at +4°C with monoclonal mouse primary
antibody against human calpastatin in concentration 1 mg/ml, titer
1:1000 (Abcam, USA) or with the anti-β-actin antibody in concen-
tration 0.5 mg/ml, titer 1:2000 (Abcam, USA) for assessment of
gel loading uniformity. After thorough washing of unbound pri-
mary antibodies with multiple changes of TBS, the membrane was
incubated with the peroxidase (HRP)-conjugated secondary anti-
body - polyclonal rabbit anti-mouse Ig (Abcam, USA), at concen-
tration 2 mg/ml and titer 1:2000. Protein-antibody binding was
detected by chemiluminescence using the SuperSignal™ kit
(Pierce, USA). Detection and recording of specific bands was per-
formed by exposing the membranes to photoradiographic film
Medical X-Ray film Foton XS-1 (Fotochemische Werke GmbH).
The developed and fixed films were digitally recorded using the
GDS-8000 System and dedicated acquisition software Labworks
Image Acquisition and Analysis Software Version 4.0 (UVP
Bioimaging System, UK). Densitometric analysis was performed
using the Scion Image Beta (version 4.0.2) program. 
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Ethical issues. All the individuals involved in the study were
informed about the purpose of the experiment and gave their con-
sent. The project was accepted by the Local Independent Commit-
tee for Ethics in Scientific Research at the Medical University of
Gdansk. 
Results
Calpain protein amount can be compared by
flow cytometry in CD4+ and CD19+ peripheral
blood lymphocytes 
Flow cytometry allows to detect and compare the
intracellular quantity of calpain protein in human
peripheral blood lymphocytes. Figure 1 presents rep-
resentative density plots of the distribution analysis
of T cells of healthy volunteer (Fig. 1A) and rheuma-
toid arthritis (RA) patient (Fig. 1B) as well as of the
CD19+ leukemia cells from a B-CLL patient (Fig.
1C), stained for intracellular calpain with combina-
tion of surface staining for CD4 or CD19 respective-
ly. The latter served as a positive control of the intra-
cellular calpain staining, based on our earlier obser-
vation of very high µ-calpain activity in these cells
[14]. The relative amount of calpain protein in the
CD4+ T cells from RA patient was lower than in
CD4+ T cells from healthy volunteers which, in turn,
was a few times lower than that detected in the 
B-CLL leukemic cells (Fig. 1D). 
Calpastatin and/or its immunoreactive cleavage
fragments can be detected by western blot
in human CD4+ and CD19+ lymphocytes 
and used for estimation of calpain activity
Western blot analysis of the lysates from immuno-
magnetically purified CD4+ or CD19+ cells allowed
for detection of both the native calpastatin (about 70
kDa) and its immunoreactive fragments (apparent
m.w. about 40 kDa) (Fig. 2). Observed quantities and
therefore proportions of the native and cleaved forms
of calpastatin were different for different cell types or
sources. Thus, in the resting CD4+ T cells isolated
from healthy people exclusively the native, 70 kDa
calpastatin was detected (Fig. 2, lane 1). while in the
CD4+ T cells isolated from RA patients usually both
forms of calpastatin - native (about 70 kDa) and
degraded (about 35-40 kDa) were found (Fig. 2, lane
2). Interestingly, in 3/19 RA patients' cell samples only
the immunoreactive calpastatin fragments, and in
another 3/19 only the native calpastatin form could be
detected. As expected, high level of calpain activity
reported earlier in the B-CLL cells resulted in practi-
cally total elimination (digestion) of native calpastatin,
leaving only its degraded immunoreactive fragments
detectable (Fig. 2, lane 3). In the latter case, in order to
show that the immunoreactive calpastatin fragments
are really the result of calpain-dependent cleavage, we
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Fig. 1. Flow cytometric detection
and comparison of calpain protein
contents in peripheral blood lym-
phocytes. Representative density
plots are shown for: CD4+ T cells
from a healthy volunteer (Fig. 1A),
patient with rheumatoid arthritis
(Fig. 1B), and for CD19+ cells of a
B-CLL patient (Fig. 1C). Due to low
contents of calpain in CD4+ T cells
both in healthy volunteers and RA
patient - the standard analysis meas-
uring the percentage of positive
cells (by putting a quadrant) could
not be applied. Therefore, the his-
togram (Fig. 1D) was used, to show
the differences in relative amounts
of intracellular calpain in gated
CD4+ cells. There, markings at the
respective histograms correspond to
these used in the density plots; H
means the healthy control, an I the
isotype control. The histogram
shows that all CD4+ T cells from
both healthy and RA individual con-
tain intracellular calpain but the
amount of calpain is different from
that expressed by B-CLL cells. 
have incubated the B-CLL cells with 2 μM membrane-
permeable calpain inhibitor (Calpain Inhibitor  IV, 
Z-LLY-FMK; Calbiochem, UK), for 24 hours at 37°C
prior to lysis. Western blot analysis of the B-CLL cells
treated that way had shown very faint traces of native
calpastatin (not shown).
Densitometric analysis of the western blot data
allowed to calculate the rate of degraded to native
forms of calpastatin as a relative coefficient of calpain
activity in CD4+ T cells isolated from RA patients. We
have found that this coefficient was 0.53 ± 0.49 (mean
± SD) for the cells of healthy individuals and 1.19 ±
1.08 for CD4+ lymphocytes of RA patients. The differ-
ence was not significant (p=0.134, N=5, Welch's mod-
ification of unpaired T test) due to relatively high vari-
ability of the results. 
Discussion
In the current study we were able to detect the pres-
ence of calpain protein in peripheral blood lympho-
cytes by flow cytometry, in combination with a surface
staining of lymphocytes. However, the presence of
enzyme does not give any information about its activ-
ity which, in the case of calpains, has a broad signifi-
cance for the functioning of many cellular systems.
Previous methods of measurements (casein zymogra-
phy and cleavage of fluorogenic substrates) allowed to
detect the total available calpain activity after separa-
tion or inhibition of calpastatin. However, the calpain-
calpastatin system works in living cells and thus a
method to detect its actual, momentous activity is
desirable as a tool for its study. We believe we found
such a method, which allows to detect the endogenous
activity of calpain in circulating peripheral blood lym-
phocytes and probably might be applied to other cell
types. 
The method we propose is similar to one utilized
for example to assess the endogenous activity of cas-
pase-3 by detecting and quantifying the degraded frag-
ments of its natural cellular substrate, the PARP
[17,18,19].
We based our method on the fact that calpastatin is
a natural, ubiquitous intracellular substrate and
inhibitor of calpain. By Western-blot technique we
were able to show both the native and degraded forms
of calpastatin in freshly isolated CD4+ T cells from
peripheral blood. CD4+ T cells from RA patients were
characterized by presence of both forms of calpastatin,
with prevalence of degraded form, and in CD4+ T cells
isolated from healthy volunteers the majority (if not
all) of calpastatin was in native form. This result sug-
gested a relatively high activity of calpain in the rest-
ing CD4+ lymphocytes of RA patients and practically
lack of such activity in the cells of healthy individuals.
Paradoxically, apparent calpain levels in the CD4+
cells of RA patients was decreased compared to that
seen in the lymphocytes of healthy individuals, while
the analysis of calpastatin degradation products sug-
gested higher activity of the enzyme in the patients'
cells. However, calpain autocleavage ('self-destruc-
tion') upon activation had been earlier reported [12].
Taken together, in our opinion low calpain contents
plus the presence of degraded calpastatin in the CD4+
cells of RA patients strongly suggests the increased
activity of the enzyme in these cells. 
Relatively high variability of the results of calcula-
tion of the proportion of degraded to native calpastatin
as a measurement of actual calpain activity in the test-
ed CD4+ cells of both healthy individuals and RA
patients may indicate additional factors (like, for
instance, the individual's age and or disease activity)
playing a role in the final result. These factors require
further study on bigger groups of both healthy and RA
individuals.
We used an already known model of high calpain
activity - the B-CLL cells, for which the extremely
high total available calpain activity was earlier meas-
ured by zymography - as a positive verification of our
method [14]. In B-CLL lysates only the degraded form
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Fig. 2. Estimation of relative calpain activity by western-blot
detection of immunoreactive fragments of calpastatin in the cell
lysates. Representative results of detection of immunoreactive
products of calpastatin cleavage by calpain, as described in Mate-
rials and methods. MW - molecular weight marker. Lanes contain
the following lysates (at equal protein content): lane 1 - CD4+ T
cells from a healthy volunteer (no endogenous calpain activity),
lane 2 - CD4+ T cells from a RA patient (low endogenous calpain
activity), lane 3 - CD19+ B cells from a B-CLL patient (high
endogenous calpain activity) , lane 4 - purified domain I of cal-
pastatin serving as standard, immunoreactive, degraded calpastatin
fragment. The native calpastatin (N, present in lanes 1 and 2) has
m.w. about 70 kDa, while the immunoreactive degraded fragments
of calpastatin (Df, present in lanes 2, 3 and 4) are about 35-40 kDa
and have a similar molecular weight to the standard. Ac - the
results of western blot detection of actin in the same samples serv-
ing as loading uniformity control.
of calpastatin was detected, with no trace of native cal-
pastatin, in accord with the notion of very high activi-
ty of the enzyme.
Obtained results are in agreement with the postu-
lated model of calpain-calpastatin balance. Thus,
cells that were containing active calpain at the
moment of harvest, did also contain calpastatin, in
either both forms: native and degraded or at least just
its degraded immunoreactive fragments. We observed
changes in proportion of native to fragmented calpas-
tatin indicating variable endogenous calpain activity
in the lymphocytes isolated from patients and healthy
volunteers. It is very likely that in the situation of
very high calpain activity (as in B-CLL cells and pos-
sibly also a few cases of RA) calpain is responsible
for such an extensive degradation of calpastatin, that
only little immunoreactive fragments can be found
inside the cells. 
Summarizing, we describe here a new approach for
detection of actual, endogenous calpain activity by
measuring the amounts of immunoreactive fragments
of calpastatin and relating it to the calpain contents in
the cells. We also demonstrate its potential usefulness
for the determination of actual calpain activity in vari-
ous cellular systems, by showing the differences
between the contents of immunoreactive fragments of
calpastatin in the lymphocytes of healthy, RA and B-
CLL individuals.
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